

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Center for Advancing Translational Sciences; Notice of Closed Meetings**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; Understudied Proteins R03.

Date: January 2, 2025.

Time: 3:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Center for Advancing Translational Sciences, National Institutes of Health, 9609 Medical Center Drive, Suite 1E504, Rockville, MD 20892 (Virtual).

Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review Administrator, Scientific Review Branch Division of Extramural Activities, National Center for Advancing Translational Sciences, National Institutes of Health, 9609 Medical Center Drive, Suite 1E504, Bethesda, MD 20892, (301) 402-1744, carol.kim@nih.gov.

Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; Review of Limited Competition CTSA R03 Applications.

Date: January 29, 2025.

Time: 11:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Center for Advancing Translational Sciences, National Institutes of Health, 9609 Medical Center Drive, Suite 1E504, Rockville, MD 20892 (Virtual).

Contact Person: Ming Yan, Ph.D., MD, Scientific Review Officer, Scientific Review Branch Division of Extramural Activities, National Center for Advancing Translational Sciences, National Institutes of Health, 9609 Medical Center Drive, Suite 1E504, Bethesda, MD 20892, (301) 451-2853, ming.yan@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: December 16, 2024.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-30320 Filed 12-18-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Biomedical Imaging and Bioengineering.

The meeting will be open to the public by videocast. The videocast link is <https://videocast.nih.gov/watch=55255>.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Biomedical Imaging and Bioengineering NACBIB, January 2025.

Date: January 22, 2025.

Open: 12:00 p.m. to 2:30 p.m.

Agenda: Report from the Institute Director, Council Members and other Institute staff.

Place: National Institutes of Health, DEM II, Suite 200, 6707 Democracy Boulevard, Bethesda, MD 20817 (Virtual Meeting).

Closed: 2:45 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, DEM II, Suite 200, 6707 Democracy Boulevard, Bethesda, MD 20817 Virtual Meeting.

Contact Person: Anna Taylor, Ph.D., Associate Director for Research Administration, Office of Research Administration, National Institute of Biomedical Imaging and Bioengineering, 6707 Democracy Boulevard, Bethesda, MD 20892, anna.taylor@nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <https://www.nibib.nih.gov/about-nibib/advisory-council>, where an agenda and any additional information for the meeting will be posted when available.

Dated: December 13, 2024.

Victoria E. Townsend,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-30079 Filed 12-18-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY**Federal Emergency Management Agency**

[Docket ID: FEMA-2024-0026]

Notice of Availability for Safe Room Construction, Supplemental Programmatic Environmental Assessment

AGENCY: Federal Emergency Management Agency, Department of Homeland Security (DHS).

ACTION: Notice of availability; request for comment.

SUMMARY: The Federal Emergency Management Agency (FEMA) has prepared a Supplemental Programmatic Environmental Assessment (SPEA) to reevaluate the analysis provided in the 2011 Final Programmatic Environmental Assessment (PEA) for Safe Room Construction and Finding of No Significant Impact (FONSI). The SPEA includes a reevaluation of the environmental analysis and underlying assumptions of the 2011 PEA. The proposed action includes the nationwide construction, retrofit, or renovation of safe rooms eligible for FEMA grant funding. FEMA has made a preliminary determination in the SPEA that the FONSI determination is valid after incorporating the updated analysis and revisions contained in the SPEA.

DATES: Substantive comments must be submitted on or before January 21, 2025 to be assured consideration.

ADDRESSES: Interested persons may submit comments responsive to this notice electronically through the Federal eRulemaking Portal at <https://www.regulations.gov>. All submissions received must include the Agency name and Docket ID. Regardless of the method used for submitting comments or material, all submissions will be posted, without change, to the Federal eRulemaking Portal at <https://www.regulations.gov>, and will include any personal information you provide.